Matrix
metalloproteinase-13 (MMP-13) plays a critical
role in the
progression of unstable atherosclerosis. A series of highly potent
and selective MMP-13 inhibitors were synthesized around a quinazoline-2-carboxamide
scaffold to facilitate radiolabeling with fluorine-18 or carbon-11
positron-emitting nuclides and visualization of atherosclerotic plaques. In vitro enzyme inhibition assays identified three compounds
as promising radiotracer candidates. Efficient automated radiosyntheses
provided [
11
C]5b, [
11
C]5f, and [
18
F]5j and enabled pharmacokinetic
characterization in atherosclerotic mice. The radiotracers displayed
substantial differences in their distribution and excretion. Most
favorably for vascular imaging, [
18
F]5j exhibited low uptake in metabolic organs
with minimal retention of myocardial radioactivity, substantial renal
clearance, and high metabolic stability in plasma. Ex vivo aortic autoradiography and competition studies revealed that [
18
F]5j specifically
binds to MMP-13 within atherosclerotic plaques and localizes to lipid-rich
regions. This study demonstrates the utility of the quinazoline-2-carboxamide
scaffold for MMP-13 selective positron emission tomography (PET) radiotracer
development and identifies [
18
F]5j for imaging atherosclerosis.